Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response

Depression and Anxiety

Volumn 32, Issue 6, 2015, Pages 400-407

  Acheson, Dean T ^a   Feifel, David ^a   Kamenski, Mary ^a   McKinney, Rebecca ^a   Risbrough, Victoria B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

anxiety anxiety disorders; CBT cognitive behavior therapy; clinical trials; pharmacotherapy; phobia phobic disorders

Indexed keywords

OXYTOCIN; PLACEBO;

ARACHNOPHOBIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXPOSURE BASED PSYCHOTHERAPY; FEAR; FEMALE; FOLLOW UP; HUMAN; MALE; PHOBIA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT RESPONSE; ADULT; ANIMAL; DRUG EFFECTS; IMPLOSIVE THERAPY; INTRANASAL DRUG ADMINISTRATION; MENTAL FUNCTION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHOBIC DISORDERS; PREMEDICATION; SPIDER; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEAR; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MENTAL PROCESSES; MIDDLE AGED; OXYTOCIN; PHOBIC DISORDERS; PREMEDICATION; SPIDERS; TREATMENT OUTCOME;

EID: 84929519086     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22362     Document Type: Article

References (61)

1. Krystal JH., Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biol Psychiat 2007; 62: 833-834.
2. Ledgerwood L, Richardson R, Cranney J,. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003; 117: 341-349.
3. Walker DL, Ressler KJ, Lu KT, Davis M,. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d -cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002 5; 22: 2343-2351.
4. Ressler KJ, Rothbaum BO, Tannenbaum L, et al., Cognitive enhancers as adjuncts to psychotherapy. Arch Gen Psychiat 2004; 61: 1136-1144.
5. Norberg MM, Krystal JH, Tolin DF,. A meta-analysis of d -cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiat 2008; 63: 1118-1126.
6. Rothbaum BO, Price M, Jovanovic T, et al., A randomized, double-blind evaluation of d -cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 2014; 171: 640-648.
7. Andero R, Ressler KJ,. Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav 2012: 11: 503-512.
8. Kuriyama K, Honma M, Soshi T, et al., Effect of d -cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. Psychopharmacology 2011; 218: 589-597.
9. Rabinak CA, Angstadt M, Sripada CS, et al., Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 2013; 64: 396-402.
10. Olff M, Langeland W, Witteveen A, Denys D,. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectrum 2010; 15: 522-530.
11. Petrovic P, Kalisch R, Singer T, Dolan RJ,. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci 2008; 28: 6607-6615.
12. Sripada CS, Phan KL, Labuschangne I, et al., Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. Int J Neuropsychopharmacol 2012; 30: 1-6.
13. Sabihi S, Durosko NE, Dong SM, Leuner, B,. Oxytocin in the prelimbic medial prefrontal cortex reduces anxiety-like behavior in female and male rats. Psychoneuroendocrinology 2014; 45: 31-42.
14. Lahoud N, Maroun M,. Oxytocinergic manipulations in corticolimbic circuit differentially affect fear acquisition and extinction. Psychoneuroendocrinology 2013; 38: 2184-2195.
15. Acheson DT, Feifel D, de Wilde S, et al., The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology 2013; 229: 199-208.
16. Eckstein M, Becker B, Scheele D, et al., Oxytocin facilitates the extinction of conditioned fear in humans. Biol Psychiat (in press).
17. Toth I, Neumann ID, Slattery DA,. Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology 2012; 223: 149-158.
18. Lahoud N, Maroun M,. Oxytocinergic manipulations in corticolimbic circuit differentially affect fear acquisition and extinction. Psychoneuroendocrinology 2013; 38: 2184-2195.
19. Striepens N, Scheele D, Kendrick KM, et al., Oxytocin facilitates protective responses to aversive social stimuli in males. Proc Natl Acad Sci 2012; 109: 18144-18149.
20. Grillon C, Krimsky M, Charney DR, et al., Oxytocin increases anxiety to unpredictable threat. Mol Psychiatr 2013; 18: 958-960.
21. Hembree EA, Rauch SAM, Foa EB,. Beyond the manual: the insider's guide to prolonged exposure therapy for PTSD. Cogn Behav Practice 2003; 10: 22-30.
22. Cloitre M, Chase Stovall-McClough K, Miranda R, Chemtob CM,. Therapeutic alliance, negative mood regulation, and treatment outcome in child abuse-related posttraumatic stress disorder. J Consult Clin Psych 2004; 72: 411-416.
23. Zoicas I, Slattery DA, Neumann ID,. Brain oxytocin in social fear conditioning and its extinction: involvement of the lateral septum. Neuropsychopharmacology 2014; 39: 3027-3035.
24. Guzman YF, Tronson NC, Sato K, et al., Role of oxytocin receptors in modulation of fear by social memory. Pyschopharmacology 2014; 231: 2097-2105.
25. Lukas M, Toth I, Reber SO, et al., The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neruopsychopharmacology 2011; 36: 2159-2168.
26. Witt DM, Winslow JT, Insel TR,. Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 1992; 43: 855-861.
27. Baumgartner T, Heinrichs M, Vonlanthen A, et al., Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008; 58: 639-650.
28. Kosfeld M, Heinrichs M, Zak PJ, et al., Oxytocin increases trust in humans. Nature 2005; 435: 673-676.
29. Bartz JA, Zaki J, Bolger N, Ochsner KN,. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 2011; 15: 301-309.
30. de Oliveira DC, Zuardi AW, Graeff FG, et al., Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol 2012; 26: 497-504.
31. Labuschagne I, Phan KL, Wood A, et al., Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharacology 2010; 35: 2403-2413.
32. Mineka S, Mystkowski JL, Hladek D, Rodriguez BI,. The effects of changing contexts on return of fear following exposure therapy for spider fear. J Consult Clin Psych 1999; 67: 599-604.
33. Merluzzi TV, Taylor CB, Boltwood M, Gotestam KG,. Opioid antagonist impedes exposure. J Consult Clin Psych 1991; 59: 425-430.
34. Mystkowski JL, Mineka S, Vernon LL, Zinbarg RE,. Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol 2003; 71: 243-250.
35. Klorman R, Hastings JE, Weerts TC, et al., Psychometric description of some specific-fear questionnaires. Behav Ther 1974; 5: 401-409.
36. Szymanski J, O'Donohue W,. Fear of spiders questionnaire. J Behav Ther Exp Psy chiatry 1995; 26: 31-34.
37. Borkovec TD, Craighead WE,. The comparison of two different methods of assessing fear and avoidance behavior. Behav Res Ther 1971; 9: 285-291.
38. Arntz A, Merckelbach H, de Jong PJ,. Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol 1993; 6: 865-870.
39. Guy W,. Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
40. Hatcher RL, Gillaspy JA,. Development and validation of a revised short version of the Working Alliance Inventory. Psychother Res 2006; 16: 12-25.
41. Borkovec TD, Nau SD,. Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry 1972; 3: 257-260.
42. Bartels A., Oxytocin and the social brain: beware the complexity. Neuropyschopharmacology 2012; 37: 1795-1796.
43. De Dreu CKW., Oxytocin modulates cooperation within and competition between groups: an integrative review and research agenda. Horm Behav 2012; 61: 419-428.
44. Eckstein M, Scheele D, Weber K, et al., Oxytocin facilitates the sensation of social stress. Hum Brain Mapp 2014; 35: 4741-4750.
45. Tabak BA, McCullough ME, Szeto A, et al., Oxytocin indexes relational distress following interpersonal harms in women. Psychoneuroendocrinology 2011; 36: 115-122.
46. Frijling JL, van Zuiden M, Koch SBJ, et al., Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial. BMC Psychiatry 2014; 14: 92.
47. Guzman YF, Tronson NC, Jovasevic V, et al., Fear-enhancing effects of septal oxytocin receptors. Nat Neurosci 2013; 16: 1185-1187.
48. Kovacs GL, Vecsei L, Telegdy G,. Opposite action of oxytocin to vasopressin in passive avoidance behavior in rats. Physiol Behav 1978; 20: 801-802.
49. Kovacs GL, Bohus B, Versteeg DH, et al., Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res 1979; 175: 303-314.
50. de Wied D, Elands J, Kovács G,. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor? Proc Natl Acad Sci 1991; 88: 1494-1498.
51. Guastella AJ, Howard AL, Dadds MR, Mitchell P,. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009; 34: 917-923.
52. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washi ngton DC: American Psychiatric Publishing; 2014.
53. MacDonald K, Feifel D,. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013; 7: 1-21.
54. Domes G, Lischke A, Berger C, et al., Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010; 35: 83-93.
55. Domes G, Heinrichs M, Glascher J, et al., Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiat 2007; 62: 1187-1190.
56. Feifel D, Macdonald K, Nguyen A, et al., Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiat 2010; 68: 678-680.
57. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R,. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41: 466-471.
58. Churchland PS, Winkleman P,. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012; 61: 392-399.
59. Neumann ID, Maloumby R, Beiderbeck DI, et al., Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 2013; 38: 1985-1993.
60. Born J, Lange T, Kern W, et al., Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-516.
61. Manning M, Misicka A, Olma A, et al., Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012; 24: 609-628.